Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose.
hypothyroidism
lactose breath test
lactose intolerance
levothyroxine
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
22 Jul 2022
22 Jul 2022
Historique:
received:
31
05
2022
revised:
11
07
2022
accepted:
15
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Purpose: to determine lactose intolerance (LI) prevalence in women with Hashimoto’s thyroiditis (HT) and assess the impact of LI on LT4 replacement dose. Methods. consecutive patients with HT underwent Lactose Breath Test and clinical/laboratory data collection. Unrelated gastrointestinal disorders were carefully ruled out. Lactose-free diet and shift to lactose-free LT4 were proposed to patients with LI. Results: we enrolled 58 females (age range, 23−72 years) with diagnosis of HT. In total, 15 patients were euthyroid without treatment, and 43 (74%) euthyroid under LT4 (30 of them with a LT4 formulation containing lactose). Gastrointestinal symptoms were present in 84.5% of patients, with a greater prevalence in change in bowel habits in lactose-intolerant patients (p < 0.0001). The cumulative LT4 dose required did not differ in patients with or without LI. No significant difference in both TSH values and LT4 dose were observed in patients shifted to lactose-free LT4 and diet at 3 and 6 months compared to baseline. Conclusion: the prevalence of LI in patients with HT was 58.6%, not different from global prevalence of LI. In the absence of other gastrointestinal disorders, LI seems not to be a major cause of LT4 malabsorption and does not affect the LT4 required dose in HT patients.
Identifiants
pubmed: 35893871
pii: nu14153017
doi: 10.3390/nu14153017
pmc: PMC9331471
pii:
doi:
Substances chimiques
Lactose
J2B2A4N98G
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Physiol. 2018 May 23;9:564
pubmed: 29875680
Aliment Pharmacol Ther. 2008 Jan 15;27(2):93-103
pubmed: 17956597
Obes Surg. 2013 Sep;23(9):1493-6
pubmed: 23824980
Autoimmun Rev. 2014 Apr-May;13(4-5):391-7
pubmed: 24434360
J Am Coll Nutr. 2000 Apr;19(2 Suppl):165S-175S
pubmed: 10759141
J Endocrinol Invest. 2007 Apr;30(4):318-22
pubmed: 17556869
J Clin Endocrinol Metab. 2014 Aug;99(8):E1454-8
pubmed: 24796930
Endokrynol Pol. 2012;63(4):318-23
pubmed: 22933169
Postgrad Med J. 2005 Mar;81(953):167-73
pubmed: 15749792
J Clin Gastroenterol. 2013 Feb;47(2):148-52
pubmed: 22495813
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):738-746
pubmed: 28690131
Am J Clin Nutr. 1988 Oct;48(4 Suppl):1079-159
pubmed: 3140651
Eur J Endocrinol. 2013 May 10;168(6):913-7
pubmed: 23554450
Endocrine. 2013 Feb;43(1):8-9
pubmed: 23097095
Autoimmun Rev. 2010 Dec;10(2):80-3
pubmed: 20696284
Med Klin (Munich). 2010 Jul;105(7):485-93
pubmed: 20676951
Endocr Metab Immune Disord Drug Targets. 2014;14(3):206-9
pubmed: 25183496
Eur J Intern Med. 2015 Oct;26(8):563-71
pubmed: 26260744
Endocrine. 2014 Jun;46(2):279-84
pubmed: 24078411
Lancet. 2000 Apr 15;355(9212):1330
pubmed: 10776747
Endocr Res. 2014;39(2):56-60
pubmed: 24067097
Aliment Pharmacol Ther. 2009 Mar 30;29 Suppl 1:1-49
pubmed: 19344474
Endocrine. 2012 Oct;42(2):252-65
pubmed: 22644837
Eur J Endocrinol. 2014 Jun;170(6):R241-52
pubmed: 24609834
Lancet. 2000 Aug 5;356(9228):510-1
pubmed: 10981918
Aliment Pharmacol Ther. 2008 Oct 15;28(8):1003-12
pubmed: 18657134
World J Gastroenterol. 2008 Oct 28;14(40):6204-7
pubmed: 18985811
Am J Gastroenterol. 2017 May;112(5):775-784
pubmed: 28323273
Br J Nutr. 2010 Sep;104(6):900-7
pubmed: 20398434
J Clin Endocrinol Metab. 2012 Mar;97(3):E419-22
pubmed: 22238404
Clin Exp Immunol. 2004 Apr;136(1):1-10
pubmed: 15030506
Eur J Endocrinol. 2006 May;154(5):633-7
pubmed: 16645008
J Gastrointestin Liver Dis. 2013 Sep;22(3):261-3
pubmed: 24078981